Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Kisunla’s active substance is donanemab, a monoclonal antibody that targets and clears amyloid-beta plaques in the brain, a ...

Eli Lilly & Company (NYSE:LLY) ranks among the best non-tech stocks to buy according to billionaires. Eli Lilly & Company ...

Eisai (OTCPK:ESALF) and Eli Lilly (NYSE:LLY) on Wednesday announced data from long-term extension studies for their ...

European regulators said that Eli Lilly’s Alzheimer’s treatment Kisunla should be approved for select patients.

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy ...

Lilly’s appeal of an earlier, negative recommendation from a key EMA committee has worked out in its favor, and puts the drug ...

Eli Lilly said on Friday that the European Medicines Agency (EMA) has recommended approval of its drug Kisunla for certain ...

For more information about Lilly Support Services and Kisunla, visit www.kisunla.lilly.com or call 1-800-LillyRx (1-800-545-5979). About Kisunla™ (donanemab) ...